Abstract: A computerized-method for reducing data inconsistency after purging client records, in Financial Institute (FI) databases, when exceeding retention period, is provided herein. The computerized-method includes operating a purge-request module. The purge-request module includes a. receiving a file including one or more customer identifications (ID); b. for each client in the received file: (i) retrieving references and links from the one or more customer-information databases to populate one or more tables with customer details based on the customer IDs; (ii) presenting a list of one or more conditions via a Graphical User Interface (GUI) of the application to enable a user to select one or more conditions for validation before purging; (iii) checking each selected condition; (iv) when the selected conditions for validation before purging are met marking the client for batch process purging; and c. purging all marked clients via a batch process.

Abstract: Sensor packages and methods of assembling sensor packages are provided. A preferred embodiment comprises: a ceramic base comprised of a platform and walls that extend up from the platform around the periphery of the platform to form a cavity; a sensor mounted to the ceramic base; a circuit board mounted down into the cavity wherein the circuit board has a hole through the board that aligns with the sensor such that the sensor is exposed to a top side of the circuit board through the hole; a plurality of electrical connections between the sensor and the circuit board; a plurality of electrical pins mounted to the circuit board and extending up above the walls of the ceramic base; and a cap mounted down into the cavity over the top of the circuit board, the cap including a window that allows the electrical pins to pass through the cap.

Abstract: Described herein is a fixed dose pharmaceutical composition containing arformoterol or its salt and a glycopyrronium salt. Particularly, a fixed dose pharmaceutical composition in the form of an aerosol or an aerosolizable for inhalation administration includes arformoterol or its salt, a glycopyrronium salt, and pharmaceutically acceptable excipients. Also described is a process for preparing the compositions and their use for the treatment of asthma and/or chronic obstructive pulmonary disease in a subject in need thereof. Also described are pharmaceutical compositions that include an effective amount of arformoterol (or its salt), a glycopyrronium salt or their combination in the form of a suspension or solution, and methods of their preparation.